SeroScience Ltd. is a spin-off company of the Semmelweis University Medical School in Budapest, Hungary, founded in 2006 by five experienced medical scientists to provide research and regulatory testing services to biotech and pharmaceutical clients and to conduct original research. SeroScience utilizes large and small animal models and state-of-the-art in vitro technologies to assess the potential of drug candidates, including intravenous drugs, biologicals, nanomedicines and contrast media, for hypersensitivity reactions and other adverse immune effects, such as antibody production (immunogenicity). The company is currently headquartered at the Semmelweis University in Budapest, and has in vivo laboratories at other locations. The company joined to EUNCL Satelitte Lab in 2018, and has participated in various national and EU grants and research projects in the field.
SeroScience Ltd. has specialized expertise in the following areas:
complement activation-related pseudoallergy (CARPA) assays
formulation of complex drugs
The field of Immunotoxicology is rapidly developing in parallel with the advancement of biopharmaceuticals and nanoformulations of small molecular drugs and imaging agents, for which immunotoxicity is a major aspect of the overall toxicity profile. Although regulatory coverage is increasing, some aspects are still in an exploratory phase and scientific insights are essential. In addition to providing testing services, SeroScience Ltd. has been a scientific leader in the field of infusion reactions that occur upon administration of the above-mentioned and other classes of therapeutic and diagnostic agents. Since 2006, our scientists have published more than 40 papers on the topic in leading journals in the field.
EUNCL Satelitte Lab